Yu, Shengyuan
Guo, Aihong
Wang, Zhen
Liu, Jianguang
Tan, Ge
Yang, Qian
Zhang, Mingjie
Yibulaiyin, Hasiyeti
Chen, Huisheng
Zhang, Yongbo
Croop, Robert
Sun, Yanhui
Liu, Yu
Zhao, Qian
Lu, Zhihong
Article History
Received: 12 December 2023
Accepted: 11 February 2024
First Online: 16 April 2024
Declarations
:
: The study protocol was approved by an Institutional Review Board or Independent Ethics Committee for each participating investigational center. All participants provided written informed consent. The study was conducted in compliance with ethical principles of the Declaration of Helsinki and all International Conference on Harmonization Good Clinical Practice Guidelines.
: Not applicable.
: Shengyuan Yu, Aihong Guo, Zhen Wang, Jianguang Liu, Ge Tan, Qian Yang, Mingjie Zhang, Hasiyeti Yibulaiyin, Huisheng Chen, and Yongbo Zhang have no competing interests to declare. Robert Croop was an employee of Biohaven Pharmaceuticals, owns stock in Biohaven Ltd., was an employee of Pfizer, has received research payments from Pfizer, and provides services to Collima LLC which has had consulting agreements with Pfizer, Aptose Biosciences Inc., Manistee Therapeutics, and Vida Ventures Management Co., L.L.C. Yanhui Sun, Yu Liu, and Qian Zhao are employees of Pfizer and own stock in Pfizer. Zhihong Lu was an employee of Bioshin (a subsidiary of Biohaven) and is currently an employee of Pfizer.